Davids MS et al. Longer term follow-up of a multicenter, phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukemia. ASH 2021;Abstract 640.
Davids MS et al. Majic: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. ASH 2021;Abstract 1553.
Davids MS et al. ReVenG: A phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia. ASH 2021;Abstract 2634.
Eichhorst B et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. ASH 2021;Abstract 71.
Flinn IW et al. Debulking before initiation of venetoclax therapy in untreated patients with chronic lymphocytic leukemia: Results from a phase 3b study. ASH 2021;Abstract 3725.
Fürstenau M et al. High resolution assessment of minimal residual disease (MRD) by next-generation sequencing (NGS) and high-sensitivity flow cytometry (hsFCM) in the phase 3 GAIA (CLL13) trial. ASH 2021;Abstract 72.
Ghia P et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 captivate study. ASH 2021;Abstract 68.
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Jacobs R et al. Efficacy and safety of ublituximab in combination with umbralisib (U2) in patients with chronic lymphocytic leukemia (CLL) by treatment status: A sub-analysis of the phase 3 Unity-CLL study. ASH 2021;Abstract 3726.
Jurczak W et al. Three-year follow-up of the Ascend trial: Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia. ASH 2021;Abstract 393.
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (ibr+ven) versus chlorambucil plus obinutuzumab (clb+o) for first-line treatment of CLL in elderly or unfit patients: The Glow study. ASH 2021;Abstract 70.
Roeker LE et al. A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach. ASH 2021;Abstract 395.
Seymour JF et al. Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 3721.
Sharma S et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). ASH 2021;Abstract 4365.
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Tedeschi A et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from arm D of the SEQUOIA (BGB-3111-304) trial. ASH 2021;Abstract 67.
Woyach JA et al. Long-term results of alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. ASH 2021;Abstract 639.